Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mizuho Medy CoTSE:4595 +0.58%81 EV-to-EBIT is 4.72 as of Aug. 24, 2026, which is 48% below its 10-year median of 9.16. GuruFocus rates TSE:4595 with a GF Score™ of 81/100 and a GF Value™ of 円1,355.15 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 694 Drug Manufacturers companies, Mizuho Medy Co ranks better than 89.05% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Mizuho Medy Co's Enterprise Value for the quarter that ended in Jun. 2026 was 円18,875 Mil.
Mizuho Medy Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円4,290 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mizuho Medy Co EV-to-EBIT Related Terms
Mizuho Medy Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Mizuho Medy Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mizuho Medy Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mizuho Medy Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mizuho Medy Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Mizuho Medy Co's EV-to-EBIT falls into.
Mizuho Medy Co's current Enterprise Value is 円20,246 Mil.
Mizuho Medy Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円4,290 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mizuho Medy Co (TSE:4595) has a EV-to-EBIT of 4.72 as of Aug. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Mizuho Medy Co and its competitors. This is 48% below median its historical median of 9.16. Over the past decade, Mizuho Medy Co's EV-to-EBIT has ranged from 1.11 to 83.70. According to the industry distribution chart, Mizuho Medy Co ranks #76 out of 694 companies in the Drug Manufacturers industry, placing it in the top 11%.
Is Mizuho Medy Co's EV-to-EBIT too high?
Mizuho Medy Co's current EV-to-EBIT of 4.72 is 48% below median its 10-year median of 9.16. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 83.70. The Drug Manufacturers industry median EV-to-EBIT is 15.66. Mizuho Medy Co's value of 4.72 is 69.9% below this industry median. Based on the distribution chart, Mizuho Medy Co ranks #76 out of 694 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mizuho Medy Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mizuho Medy Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mizuho Medy Co ranks #76 out of 694 companies for EV-to-EBIT. This places Mizuho Medy Co in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.66. Mizuho Medy Co's value of 4.72 is 69.9% below this benchmark. Historically, Mizuho Medy Co's own EV-to-EBIT has ranged from 1.11 to 83.70 over the past decade. While the company's 10-year median is 9.16 vs. the industry median of 15.66, Mizuho Medy Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.66, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mizuho Medy Co's current EV-to-EBIT of 4.72 is 69.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Mizuho Medy Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mizuho Medy Co's current EV-to-EBIT is 4.72, which is 48% below median its own 10-year median of 9.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mizuho Medy Co stock overvalued right now?
Based on GuruFocus' analysis, Mizuho Medy Co (TSE:4595) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,355.15, compared to a current price of 円1,721.00 — trading 27% above its estimated fair value. The current EV-to-EBIT is 4.72, which is 48% below median its 10-year median of 9.16 and 69.9% below the Drug Manufacturers industry median of 15.66. Mizuho Medy Co's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Mizuho Medy Co (TSE:4595), the current EV-to-EBIT is 4.72 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mizuho Medy Co (TSE:4595) Overvalued in 2026?
Based on GuruFocus' analysis, Mizuho Medy Co stock appears to be overvalued.
The current stock price of 円1,721.00 is trading 27% above its estimated GF Value™ of 円1,355.15.
GuruFocus considers Mizuho Medy Co to be Modestly Overvalued.
Key valuation signals for TSE:4595:
EV-to-EBIT: 4.72 (48% below median its 10-year median of 9.16)
GF Value™: 円1,355.15 vs. price of 円1,721.00 (27% above fair value)
Industry Position: 69.9% below the Drug Manufacturers median (#76 of 694)
No single metric tells the full story. See the TSE:4595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mizuho Medy Co Ltd engages in research and development, manufacture, and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including a digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.
81GF Score
Get the complete analysis for TSE:4595
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4595 has been successfully added to your 
